Toronto Dominion Bank Buys Shares of 58,332 Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Toronto Dominion Bank acquired a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,332 shares of the company's stock, valued at approximately $1,131,000. Toronto Dominion Bank owned 0.17% of Oruka Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. FMR LLC increased its position in Oruka Therapeutics by 17.7% during the fourth quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after acquiring an additional 830,000 shares during the period. Fairmount Funds Management LLC raised its holdings in Oruka Therapeutics by 5.0% during the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares during the last quarter. RTW Investments LP increased its stake in shares of Oruka Therapeutics by 5.1% in the 4th quarter. RTW Investments LP now owns 1,945,649 shares of the company's stock valued at $37,726,000 after acquiring an additional 95,001 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after acquiring an additional 1,572,853 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock valued at $25,730,000 after purchasing an additional 1,047,245 shares during the period. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Trading Up 3.4%

Shares of ORKA traded up $0.39 during trading hours on Thursday, hitting $11.86. The company had a trading volume of 32,312 shares, compared to its average volume of 224,152. The company's fifty day moving average price is $9.75 and its two-hundred day moving average price is $13.97. Oruka Therapeutics, Inc. has a one year low of $5.49 and a one year high of $31.13. The company has a market capitalization of $443.86 million, a PE ratio of -1.89 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Analysts forecast that Oruka Therapeutics, Inc. will post -3.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Wolfe Research started coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price target on the stock. Wedbush restated an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a research report on Thursday, May 15th. Wall Street Zen raised Oruka Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. HC Wainwright restated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, BTIG Research started coverage on Oruka Therapeutics in a report on Thursday, May 22nd. They issued a "buy" rating for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.